TRMT13

Across TCGA pan-cancer cohorts, TRMT13 mass-spec protein differs between tumor and matched normal tissue in 5 of 18 cancer types tested, making tumor–normal expression one of TRMT13’s most consistent transcriptional readouts.

The strongest signal is observed in lung squamous cell carcinoma (LSCC), where TRMT13 mass-spec protein is more highly expressed in tumor relative to normal tissue. In most cancer types TRMT13 is over-expressed in tumor, although a few such as PDAC show the opposite, repressed pattern.

LSCC, PDAC, and CCRCC are the cancer types where TRMT13 tumor–normal differential expression is most reproducible.

mass-spec protein tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in TRMT13 mass-spec protein (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
LSCC	Male	II,III,IV	+0.411	<.001	8	view →
PDAC	Male	All	−0.523	<.001	7	view →
CCRCC	Male	All	+0.190	<.001	6	view →
LUAD	All	All	+0.120	.005	3	view →
HNSC	Male	III,IV	+0.239	.027	2	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 5 strongest of 5 lineages.

TRMT13–LSCC

Open the LSCC breakdown →